AR035756A1 - Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos - Google Patents

Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos

Info

Publication number
AR035756A1
AR035756A1 ARP020100697A ARP020100697A AR035756A1 AR 035756 A1 AR035756 A1 AR 035756A1 AR P020100697 A ARP020100697 A AR P020100697A AR P020100697 A ARP020100697 A AR P020100697A AR 035756 A1 AR035756 A1 AR 035756A1
Authority
AR
Argentina
Prior art keywords
carbamates
preparation
group
neurodegenerative disorders
medicines
Prior art date
Application number
ARP020100697A
Other languages
English (en)
Spanish (es)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR035756A1 publication Critical patent/AR035756A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP020100697A 2001-02-27 2002-02-27 Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos AR035756A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27168201P 2001-02-27 2001-02-27
US10/081,764 US20020165273A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
AR035756A1 true AR035756A1 (es) 2004-07-07

Family

ID=26765943

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100697A AR035756A1 (es) 2001-02-27 2002-02-27 Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos

Country Status (26)

Country Link
US (3) US20020165273A1 (enExample)
EP (1) EP1383489B1 (enExample)
JP (1) JP4276840B2 (enExample)
KR (1) KR100910928B1 (enExample)
CN (1) CN1235579C (enExample)
AR (1) AR035756A1 (enExample)
AT (1) ATE361745T1 (enExample)
BR (1) BR0207645A (enExample)
CA (1) CA2439295C (enExample)
CY (1) CY1106753T1 (enExample)
CZ (1) CZ301203B6 (enExample)
DE (1) DE60220043T2 (enExample)
DK (1) DK1383489T3 (enExample)
ES (1) ES2284845T3 (enExample)
HU (1) HUP0303264A3 (enExample)
IL (2) IL157591A0 (enExample)
MX (1) MXPA03007718A (enExample)
MY (1) MY138156A (enExample)
NO (1) NO20033798L (enExample)
NZ (1) NZ527990A (enExample)
PL (1) PL364680A1 (enExample)
PT (1) PT1383489E (enExample)
RS (1) RS51055B (enExample)
RU (1) RU2300373C2 (enExample)
TW (1) TWI312679B (enExample)
WO (1) WO2002067925A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
PT1809273E (pt) * 2004-09-16 2010-05-10 Janssen Pharmaceutica Nv Utililização de 2-fenil-1,2-etanodiol-(di)carbamatos para tratamento de epileptogénese
BRPI0516112A (pt) * 2004-10-15 2008-08-26 Janssen Pharmaceutica Nv métodos para neuroproteção
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
EP1928451B1 (en) * 2005-07-26 2011-12-28 SK Biopharmaceuticals Co., LTD Methods for treating substance-related disorders
US7632963B2 (en) * 2006-10-06 2009-12-15 Janssen Pharmaceutica Nv Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
CN101568362A (zh) * 2006-10-30 2009-10-28 詹森药业有限公司 治疗抑郁症的方法
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
WO2012002773A2 (en) * 2010-07-02 2012-01-05 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
WO2013036678A1 (en) * 2011-09-07 2013-03-14 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
RU2632659C2 (ru) 2011-12-27 2017-10-09 Байо-Фарм Солюшнс Ко., Лтд. Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
JP6062077B2 (ja) * 2013-03-12 2017-01-18 バイオ−ファーム ソリューションズ カンパニー リミテッド 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｐｅｄｉａｔｒｉｃｅｐｉｌｅｓｙａｎｄｅｐｉｌｅｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅｓ｝
WO2014142547A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for neuroprotection comprising the same
CN109071424B (zh) 2016-02-29 2022-01-14 生物药品解决方案有限公司 氨基磺酸酯衍生物化合物、其制备方法及用途
ES3035674T3 (en) 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
IL281559B2 (en) * 2018-09-21 2025-06-01 Sk Biopharmaceuticals Co Ltd (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
WO2022045824A1 (en) 2020-08-31 2022-03-03 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
US11896593B2 (en) 2020-09-10 2024-02-13 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3278380A (en) * 1962-02-06 1966-10-11 Armour Pharma Methods of calming employing diphenyl hydroxy carbamate compounds
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
CN1109880A (zh) * 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
RS50676B (sr) * 2001-02-27 2010-06-30 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
DK1401424T3 (da) * 2001-02-27 2007-02-26 Ortho Mcneil Pharm Inc Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af psykotiske forstyrrelser
HUP0303243A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing and treating bipolar disorder

Also Published As

Publication number Publication date
DE60220043T2 (de) 2008-01-10
CZ301203B6 (cs) 2009-12-09
JP2004523555A (ja) 2004-08-05
KR100910928B1 (ko) 2009-08-06
DE60220043D1 (de) 2007-06-21
CN1235579C (zh) 2006-01-11
NO20033798L (no) 2003-09-26
IL157591A (en) 2009-12-24
ES2284845T3 (es) 2007-11-16
BR0207645A (pt) 2004-12-28
JP4276840B2 (ja) 2009-06-10
ATE361745T1 (de) 2007-06-15
HUP0303264A2 (hu) 2004-01-28
US20040171679A1 (en) 2004-09-02
RU2300373C2 (ru) 2007-06-10
RU2003128982A (ru) 2005-03-10
HK1065486A1 (en) 2005-02-25
CN1503667A (zh) 2004-06-09
PL364680A1 (en) 2004-12-13
CZ20032313A3 (cs) 2004-08-18
US20020165273A1 (en) 2002-11-07
CY1106753T1 (el) 2012-05-23
WO2002067925A1 (en) 2002-09-06
HK1060516A1 (en) 2004-08-13
NZ527990A (en) 2006-01-27
NO20033798D0 (no) 2003-08-26
CA2439295C (en) 2010-05-25
TWI312679B (en) 2009-08-01
US20090005442A1 (en) 2009-01-01
HUP0303264A3 (en) 2012-07-30
MY138156A (en) 2009-04-30
RS67403A (sr) 2006-12-15
PT1383489E (pt) 2007-06-21
IL157591A0 (en) 2004-03-28
EP1383489B1 (en) 2007-05-09
EP1383489A1 (en) 2004-01-28
CA2439295A1 (en) 2002-09-06
MXPA03007718A (es) 2004-11-12
DK1383489T3 (da) 2007-08-06
RS51055B (sr) 2010-10-31
KR20030076714A (ko) 2003-09-26

Similar Documents

Publication Publication Date Title
AR033426A1 (es) Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento
AR035532A1 (es) Diaminotiazoles, composiciones farmaceuticas que los comprenden, intermediarios para la preparacion de dichos compuestos, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos
BR0207645A (pt) Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos
NO20080877L (no) Fremgangsmater for behandling av substansrelaterte forstyrrelser
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
MY133370A (en) Carbamate compounds for use in preventing or treating bipolar disorders
BR0207644A (pt) Compostos de carbamato para uso na prevenção ou no tratamento de distúrbio bipolar
BR0207673A (pt) Compostos de carbamato para o uso no tratamento de dor
PT1399144E (pt) Compostos carbamato para utilizacao na prevencao ou tratamento de disturbios de ansiedade
AR032876A1 (es) Compuestos de carbamato para utilizar en la prevencion o tratamiento de los trastornos psicoticos
AR054550A1 (es) Metodos para tratar la epileptogenesis
BR0112713A (pt) "compostos de carbamato para uso na prevenção ou tratamento de dor neuropática e dor associada a cefaléia em cacho e hemicrânia
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
BR0211240A (pt) Compostos de carbamato para uso na prevenção ou tratamento de dor neuropática e dor associada à cefaléia em cacho e hemicrânia
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
BR0211244A (pt) Compostos de carbamato para uso na prevenção ou tratamento de dor neuropática e dor associada com cefaléia em salvas e enxaqueca
AR032907A1 (es) Uso de compuestos carbamatos para la prevencion o tratamiento de trastornos de ansiedad
AR035757A1 (es) Uso de carbamatos para la fabricacion de medicamentos para prevenir o tratar un trastorno bipolar
AR033428A1 (es) Compuestos carbamatos para su uso en la prevencion o tratamiento de trastornos bipolares
AR034785A1 (es) Compuestos de carbamato para utilizarse en la prevencion o tratamiento de dolor neuropatico y dolor asociado con cefalea migranosa y cefalea acuminada
AR033545A1 (es) Uso de compuestos de carbamato para la fabricacion de medicamentos
AR034786A1 (es) Compuestos de carbamato para utilizarse en la prevencion o tratamiento de dolor neuropatico y dolor asociado con cefalea migranosa y cefalea acuminada
MY136347A (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain

Legal Events

Date Code Title Description
FB Suspension of granting procedure